vs
Side-by-side financial comparison of Caribou Biosciences, Inc. (CRBU) and CaliberCos Inc. (CWD). Click either name above to swap in a different company.
CaliberCos Inc. is the larger business by last-quarter revenue ($4.1M vs $3.9M, roughly 1.0× Caribou Biosciences, Inc.). CaliberCos Inc. runs the higher net margin — -188.3% vs -672.1%, a 483.8% gap on every dollar of revenue. On growth, Caribou Biosciences, Inc. posted the faster year-over-year revenue change (89.7% vs -52.5%). Over the past eight quarters, Caribou Biosciences, Inc.'s revenue compounded faster (27.4% CAGR vs -57.6%).
Caribou Biosciences, Inc. is a clinical-stage biotechnology company focused on developing CRISPR genome-edited cell therapies for cancers and autoimmune diseases. It operates mainly in North American and European markets, partnering with leading pharmaceutical enterprises to advance its pipeline of accessible, targeted therapeutic products for global patients.
CaliberCos Inc. is a U.S.-headquartered alternative asset management firm focused primarily on real estate investments. It offers a diverse suite of investment vehicles covering commercial, residential, and industrial real estate assets, serving institutional investors, high-net-worth individuals, and retail clients across North America. It also delivers asset management, property operation, and value-add real estate development services to support consistent long-term returns for investors.
CRBU vs CWD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $4.1M |
| Net Profit | $-26.5M | $-7.7M |
| Gross Margin | — | — |
| Operating Margin | -722.0% | -196.6% |
| Net Margin | -672.1% | -188.3% |
| Revenue YoY | 89.7% | -52.5% |
| Net Profit YoY | 25.4% | 32.2% |
| EPS (diluted) | $-0.28 | $1.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $4.1M | ||
| Q3 25 | $2.2M | $3.6M | ||
| Q2 25 | $2.7M | $5.1M | ||
| Q1 25 | $2.4M | $7.3M | ||
| Q4 24 | $2.1M | $8.7M | ||
| Q3 24 | $2.0M | $11.3M | ||
| Q2 24 | $3.5M | $8.2M | ||
| Q1 24 | $2.4M | $23.0M |
| Q4 25 | $-26.5M | $-7.7M | ||
| Q3 25 | $-27.5M | $-4.4M | ||
| Q2 25 | $-54.1M | $-5.3M | ||
| Q1 25 | $-40.0M | $-4.4M | ||
| Q4 24 | — | $-11.4M | ||
| Q3 24 | $-34.7M | $146.0K | ||
| Q2 24 | $-37.7M | $-4.7M | ||
| Q1 24 | $-41.2M | $-3.8M |
| Q4 25 | -722.0% | -196.6% | ||
| Q3 25 | -1337.6% | -129.6% | ||
| Q2 25 | -1784.0% | -112.4% | ||
| Q1 25 | -1823.8% | -62.7% | ||
| Q4 24 | — | -236.8% | ||
| Q3 24 | -1889.2% | 0.0% | ||
| Q2 24 | -1255.8% | -65.0% | ||
| Q1 24 | -1893.9% | -22.9% |
| Q4 25 | -672.1% | -188.3% | ||
| Q3 25 | -1253.3% | -120.2% | ||
| Q2 25 | -2028.4% | -104.5% | ||
| Q1 25 | -1699.6% | -60.7% | ||
| Q4 24 | — | -247.6% | ||
| Q3 24 | -1713.6% | 1.3% | ||
| Q2 24 | -1088.3% | -57.8% | ||
| Q1 24 | -1697.6% | -16.6% |
| Q4 25 | $-0.28 | $1.95 | ||
| Q3 25 | $-0.30 | $-1.65 | ||
| Q2 25 | $-0.58 | $-4.15 | ||
| Q1 25 | $-0.43 | $-3.85 | ||
| Q4 24 | — | $-10.15 | ||
| Q3 24 | $-0.38 | $0.12 | ||
| Q2 24 | $-0.42 | $-4.34 | ||
| Q1 24 | $-0.46 | $-3.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $12.4M | $2.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $122.2M | $1.3M |
| Total Assets | $175.4M | $135.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $12.4M | $2.9M | ||
| Q3 25 | $11.1M | $10.9M | ||
| Q2 25 | $25.2M | $683.0K | ||
| Q1 25 | $29.4M | $1.6M | ||
| Q4 24 | $16.3M | $2.3M | ||
| Q3 24 | $32.0M | $1.6M | ||
| Q2 24 | $37.9M | $1.8M | ||
| Q1 24 | $49.4M | $2.1M |
| Q4 25 | $122.2M | $1.3M | ||
| Q3 25 | $141.8M | $4.2M | ||
| Q2 25 | $166.1M | $-19.9M | ||
| Q1 25 | $217.2M | $-15.8M | ||
| Q4 24 | $253.0M | $-12.6M | ||
| Q3 24 | $281.2M | $-3.8M | ||
| Q2 24 | $310.5M | $-4.7M | ||
| Q1 24 | $343.3M | $-745.0K |
| Q4 25 | $175.4M | $135.4M | ||
| Q3 25 | $195.0M | $82.6M | ||
| Q2 25 | $220.9M | $59.3M | ||
| Q1 25 | $273.7M | $103.6M | ||
| Q4 24 | $313.3M | $105.5M | ||
| Q3 24 | $344.3M | $158.6M | ||
| Q2 24 | $372.9M | $195.2M | ||
| Q1 24 | $406.8M | $201.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-20.8M | $-12.1M |
| Free Cash FlowOCF − Capex | $-21.0M | — |
| FCF MarginFCF / Revenue | -533.9% | — |
| Capex IntensityCapex / Revenue | 5.5% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-112.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-20.8M | $-12.1M | ||
| Q3 25 | $-25.2M | $-4.6M | ||
| Q2 25 | $-28.3M | $-1.2M | ||
| Q1 25 | $-36.7M | $-1.7M | ||
| Q4 24 | $-138.2M | $555.0K | ||
| Q3 24 | $-32.7M | $-74.0K | ||
| Q2 24 | $-32.9M | $1.4M | ||
| Q1 24 | $-37.2M | $-1.5M |
| Q4 25 | $-21.0M | — | ||
| Q3 25 | $-25.3M | — | ||
| Q2 25 | $-28.7M | — | ||
| Q1 25 | $-37.8M | — | ||
| Q4 24 | $-143.1M | — | ||
| Q3 24 | $-33.3M | — | ||
| Q2 24 | $-35.1M | — | ||
| Q1 24 | $-38.7M | — |
| Q4 25 | -533.9% | — | ||
| Q3 25 | -1151.0% | — | ||
| Q2 25 | -1075.2% | — | ||
| Q1 25 | -1605.1% | — | ||
| Q4 24 | -6888.8% | — | ||
| Q3 24 | -1646.9% | — | ||
| Q2 24 | -1013.5% | — | ||
| Q1 24 | -1591.2% | — |
| Q4 25 | 5.5% | — | ||
| Q3 25 | 5.2% | — | ||
| Q2 25 | 15.7% | — | ||
| Q1 25 | 44.3% | — | ||
| Q4 24 | 235.0% | — | ||
| Q3 24 | 33.3% | — | ||
| Q2 24 | 64.7% | — | ||
| Q1 24 | 59.6% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -0.51× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
